Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

86.10 -2.13 (-2.41%)
Official Closing Price Updated: 4:10 PM EST, Feb 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,944,137
Open 86.58
Bid (Size) 86.02 (1)
Ask (Size) 88.12 (1)
Prev. Close 88.23
Today's Range 85.59 - 86.59
52wk Range 74.09 - 94.26
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Liposome Drug Delivery Market 2023 in-Depth Analysis, Growth, Size, Future Prospect, Regional Development and Global Outlook 2029
Liposome Drug Delivery Market Size, Share and Forecast 2023-2029 Key Players are – Ipsen Pharma, Celsion Corp, Gilead Sciences, Astellas Pharma, Johnson & Johnson, Luye Pharma Group, Novartis AG 
Via SBWire
Exposures COVID-19
Shigella Vaccines Market: Study Navigating the Future Growth Outlook
Get Shigella Vaccines Market analysis, key vendors & competitive scenario of the market prepared using market research tools such as Porter’s five forces and SWOT analysis. 
Via SBWire

Performance

YTD
-6.63%
-6.63%
1 Month
-6.63%
-6.63%
3 Month
+6.84%
+6.84%
6 Month
+1.46%
+1.46%
1 Year
-2.36%
-2.36%

More News

Read More
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
Via Investor's Business Daily
Nasdaq Futures Fly As Meta Keeps Tech Earnings' Buoyancy Intact: Will Apple, Amazon, Alphabet Toe In Line?
Via Benzinga
Novartis Ag (NVS) Q4 2022 Earnings Call Transcript
Via The Motley Fool
Novartis Reports Mixed Bag Q4 Earnings, Forecasts Higher Sales, Profits Ahead Of Sandoz Spin-Off
Via Benzinga
Pharma Giants GSK, Novo Nordisk Beat Expectations; But Novartis Dives On A Mixed Report
Via Investor's Business Daily
Rancho Biosciences Welcomes BenevolentAI as New Member to Its Single Cell Data Science Consortium
Via Newswire.com
US Stocks On Track For Nervous Start As Traders Go Fed Watching: AMD Earnings Calm Investors
Via Benzinga
Envision Pharma Group Hires Leading Industry Executives Dominic Marasco and Gregory Carpenter to Lead Further Expansion of the Business and Support Growing Customer Demand
Via Newswire.com
Earnings Scheduled For February 1, 2023
Via Benzinga
A Preview Of Novartis's Earnings
Via Benzinga
7 CRISPR Stocks With the Best Long-Term Potential
Via InvestorPlace
Philips Reports Q4 Earnings, To Lay Off Additional Employees This Year, Shares Jump
Via Benzinga
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
Via Benzinga
Could This Be Novartis' Next Blockbuster Medicine?
Via The Motley Fool
Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
Via MarketBeat
Sandoz Acquires Antifungal Agent From Astellas, Reinforcing Hospital Offering
Via Benzinga
3 Drug Stocks With Promising Pipelines for 2023
Via InvestorPlace
Clearmind Teams With Yissum, University of Jerusalem On 2 Psychedelic R&D Projects
Via Benzinga
Analyst Views Novo Nordisk's Upcoming Obesity Drug Data To Lay Grounds For Eli Lilly's Tirzepatide
Via Benzinga
National Advertising Division Finds Novartis Breast Cancer Drug Claim Supported in Physician-Directed Messaging, But Not in Ads to Consumers
Via iCrowdNewswire
Drug Delivery Market – Major Technology Giants in Buzz Again : Johnson & Johnson, Sanofi, Pfizer
Via SBWire
Cell and Gene Therapy Market Size, Share, Industry Analysis, Growth Estimates, Trends, Demand and Forecast 2022-2028
Via SBWire
Novartis CEO Refutes Recent Report Of Weighing Options For Ophthalmology, Respiratory Units
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.